Bose Launches New QuietComfort Earbuds with Wireless Charging
The $299 second-generation QuietComfort Ultra Earbuds will be released this summer along with the second-generation SoundLink Micro Speaker for $129, the company said in a statement Thursday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
OLIVE YOUNG Brings Leading K-Beauty Brands and "All Live Young" Philosophy to KCON LA 2025 as Title Sponsor
LOS ANGELES, Aug. 1, 2025 /PRNewswire/ -- OLIVE YOUNG, South Korea's leading beauty and wellness retailer, returns as the title sponsor of KCON LA 2025, bringing its signature "All Live Young" philosophy to life through a dynamic and immersive K-beauty experience in the heart of Los Angeles. This activation marks a major milestone in the brand's journey to bring its trusted K-beauty experience to North America, with its first U.S. store set to open in Los Angeles in late H1 2026. The brand's presence at KCON reflects its commitment to making K-beauty more accessible, inclusive, and experience-driven for global audiences. At KCON LA, OLIVE YOUNG will spotlight a total of 66 brands including their award-winning private label brands—BIOHEAL BOH, BRINGGREEN, and COLORGRAM— where 164 products from 64 brands will be featured through immersive, interactive zones designed to introduce U.S. audiences to the brand's curated approach to skincare, color, and wellness. Booth Highlights Include:K-Skincare Starter Kit: "Beauty Box" Pop-Up with Global App IntegrationAs part of the pop-up experience, attendees are invited to discover OLIVE YOUNG's "Beauty Box," a curated starter kit featuring standout products from six K-beauty brands available in the U.S. assortment, including Biodance, numbuzin, and ROUND LAB. Guests who engage in the experience will have the opportunity to extend their discovery journey through the OLIVE YOUNG Global website and app, where a limited-time exclusive chance to explore a pop-up offering will be available. Core Skincare Showcase: A Glimpse into the First U.S. StoreA dedicated zone spotlights OLIVE YOUNG's four essential skincare categories—Essence & Serum, Sun Care, Sheet Masks & Pads, and Creams—offering a first look at hero SKUs likely to be included in the upcoming U.S. retail launch.. Exclusive Experience Zones: Discover OLIVE YOUNG's Private BrandsVisitors can immerse themselves in interactive brand zones from OLIVE YOUNG's top-performing private labels: BIOHEAL BOH: Explore anti-aging and lifting solutions in the BIOHEAL BOH Lab. BRINGGREEN: Get personalized skin trouble diagnosis at the BRINGGREEN Nurse's Office. COLORGRAM: Play with high-quality color at COLORGRAM's Colorful Art Room. "We're excited to bring our 'All Live Young' philosophy to life at KCON LA 2025 through curated products, thoughtful retail innovation, and a focus on experience," said Sehoon Jin, Executive Vice President of Global Platform Business at OLIVE YOUNG. "This is a meaningful step in bringing OLIVE YOUNG's trusted and inclusive K-beauty experience to the U.S. market." For more information about OLIVE YOUNG and its private label brands, visit ABOUT OLIVE YOUNG: Established in 1999, OLIVE YOUNG is South Korea's leading beauty and health retailer, dedicated to helping everyone live a healthy and beautiful life. The brand philosophy, "All Live Young," reflects OLIVE YOUNG's vision of inspiring customers to embrace wellness and beauty at every stage of life. Through its flagship store and online platforms, OLIVE YOUNG offers a curated selection of trendy and innovative K-beauty and wellness products, loved by customers worldwide. With over 1,370 stores, more than 20 years of expertise, and strong global partnerships, OLIVE YOUNG continues to set the standard for innovation, accessibility, and customer-focused retail in the K-beauty and wellness industry. As part of CJ Group, a global lifestyle company based in South Korea, OLIVE YOUNG delivers the value of healthy beauty to customers everywhere. MEDIA CONTACT: For more information and interview requests, please contact PURPLE: oliveyoung@ View original content to download multimedia: SOURCE OLIVE YOUNG Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
12 minutes ago
- Yahoo
DEA Accountability as Cannabis Research Crisis Deepens And Patients Suffer
With the confirmation of incoming DEA Administrator Terrance Cole, the opportunity for reform has arrived. The DEA must choose between outdated drug war politics and advancing public health. MMJ International Holdings Issues Clarification on Irvine Labs. WASHINGTON, DC / / August 1, 2025 / MMJ International Holdings, Inc. ("MMJ") today issued a public clarification regarding prior statements about Irvine Labs, Inc., while calling for an urgent reckoning with the U.S. Drug Enforcement Administration's (DEA) catastrophic mismanagement of America's cannabis research policy. In a previous press release, MMJ referenced widespread inactivity among DEA-registered marijuana manufacturers. While these statements were intended to highlight systemic failures within the DEA's quota and licensing system, MMJ acknowledges that this language may have unintentionally caused confusion regarding Irvine Labs, Inc. MMJ hereby clarifies that Irvine Labs, Inc. is a registered DEA entity and, to the best of MMJ's current knowledge, holds valid DEA registrations. MMJ did not intend to imply that Irvine Labs is inactive or insolvent, and any interpretation suggesting otherwise is hereby retracted. This clarification, however, does not alter the underlying crisis: the DEA's marijuana manufacturing quota system is fundamentally broken. Despite a supposed expansion of DEA licenses, no registrant-except MMJ-has produced sufficient pharmaceutical-grade cannabis to support a single FDA-compliant clinical trial. The Devastating Reality: Maridose (Maine): Only 1,100 sq. ft. of space, not growing. Bright Green Corp: Surrendered its registration without ever planting a crop. Royal Emerald Pharmaceuticals: Inactive and facing financial distress. Groff NA Hemplex & Scottsdale Research Institute: No active cultivation for clinical trials. BRC: Producing quantities far below clinical thresholds. University of Mississippi: Continues to grow substandard, research-incompatible marijuana. MMJ remains the only federally compliant entity actively pursuing the cultivation of strain-specific, pharmaceutical-grade cannabis for FDA-approved clinical trials targeting Huntington's Disease and Multiple Sclerosis. Yet, for over seven years, the DEA has obstructed MMJ's efforts through unconstitutional administrative proceedings, arbitrary quotas, and a bureaucratic "Catch-22" that demands documentation (BFSA) which is unattainable without the very registration the DEA refuses to grant. A Constitutional Crisis Exposed The Supreme Court's rulings in Axon v. FTC and Jarkesy v. SEC have now exposed the DEA's internal administrative law judge (ALJ) system as an unconstitutional charade. Despite this, DEA legal counsel Aarathi Haig continues to defend a system the Department of Justice has now abandoned. Former Chief ALJ John "McLooney" Mulrooney has since retired, leaving behind what critics call a "legal dumpster fire." MMJ's legal exceptions, filed July 3, 2025, detail the agency's structural bias, retroactive sabotage, and deliberate obstruction of medical research. "We followed every law, built the FDA-inspected facility, and secured our clinical approvals," said Duane Boise, CEO of MMJ International Holdings. "What the DEA calls regulation is nothing more than bureaucratic revenge." The Time for Reckoning is Now With the confirmation of incoming DEA Administrator Terrance Cole, the opportunity for reform has arrived. The DEA must choose between outdated drug war politics and advancing public health. This demands immediate action: Fire entrenched obstructionists like Thomas Prevoznik. Investigate Aarathi Haig for perpetuating unconstitutional legal processes. Transfer oversight of cannabis research to the FDA, where science-not sabotage-will guide policy. "The DEA has spent a decade fortifying a broken system that protects monopolies, obstructs innovation, and ignores public safety disasters like the Assured Testing Labs scandal in Massachusetts," said Boise. "America doesn't need another anti-marijuana crooner in a suit-it needs a leader who will stand up to this agency's sabotage and put patients first." MMJ International Holdings remains committed to factual accuracy and will continue to expose systemic failures that endanger patients, stifle science, and betray the public trust. MMJ is represented by attorney Megan Sheehan. CONTACT:Madison HiseyMHisey@ SOURCE: MMJ International Holdings View the original press release on ACCESS Newswire Sign in to access your portfolio
Yahoo
12 minutes ago
- Yahoo
Economists Flip To Trump's Side After Jobs Data–And Jerome Powell Is Now In Trouble
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Just two days after Fed Chair Jerome Powell refused to pre-commit to a September rate cut, the U.S. labor market did it for him. SPY ETF breaks past support. See real-time price here. A weak July jobs report and the biggest downward 2-month revisions since 2020 have economists—and markets—racing to President Donald Trump's side on calling for lower interest rates. Labor Data Breaks Down And Manufacturing Is Not Helping Either The U.S. economy added just 73,000 jobs in July, far below the 110,000 expected. But the real shock came from the Bureau of Labor Statistics revising May and June non-farm payrolls down by a combined 258,000—erasing what were thought to be solid job gains. This is the largest two-month revision since the COVID-19 shock in 2020. Trending: Be part of the breakthrough that could replace plastic as we know it— Private-sector job growth was narrowly concentrated, driven largely by healthcare, while government payrolls fell by 10,000. The unemployment rate edged up to 4.2%, reversing June's drop. Wages, however, remained hot. Average hourly earnings rose 0.3% month-over-month and 3.9% year-over-year, both beating forecasts. Still, signs of underlying weakness in the labor force—especially due to declining immigration—are mounting. Meanwhile, U.S. manufacturing continues to struggle, signaling ongoing headwinds from tariff-driven uncertainty. The ISM Manufacturing PMI decreased to 48 in July 2025, down from 49 in June and below the expected level of 49.5. It marked the fifth straight month of contraction and the lowest reading since October 2024. Wall Street Moves To The Dovish Side Markets are now fully pricing in two rate cuts by December, with the chance of a September 25-basis-point cut surging to 76% Friday, more than double Thursday's odds. Oxford Economics' Nancy Vanden Houten said the weak July report and historic revisions "raise the odds of a Fed rate cut in September." She warned that slower labor force growth, especially among foreign-born workers, may mask deeper structural issues."The foreign-born labor force has shrunk by 1.2 million in just six months," she said, linking the decline to the Trump administration's immigration policies. "Powell's take on September not being a live meeting might be under revision as we speak," said BOK Financial's analyst Steve Wyett, citing the sharp downward revisions. David Russell, analyst at TradeStation, indicated that "huge negative revisions undermine beliefs about the strength of the labor market," but warned that "there are still signs of stagflation, with hourly earnings up more than expected." Jamie Cox, managing partner for Harris Financial Group, weighed in. "Powell is going to regret holding rates steady this week. September is a lock for a rate cut—and it might even be 50 basis points." Bill Adams, chief economist at Comerica Bank, struck a more cautious tone. He said the weak July jobs report adds pressure on the Fed to cut rates later this year, but warned the decision "isn't a slam dunk." Adams said the Fed will closely watch the August jobs report and inflation data before making its next move. Yields on two-year Treasury bonds, which are highly sensitive to interest-rate expectations, tumbled 22 basis points to 3.75%, eyeing the largest intraday drop since August 2024. The U.S. dollar index – as closely tracked by the Invesco DB USD Index Bullish Fund ETF (NYSE:UUP) – fell 1.2% by 10:30 a.m. in New York, trimming weekly gains. Read Next: $100k+ in investable assets? Match with a fiduciary advisor for free to learn how you can maximize your retirement and save on taxes – no cost, no obligation. Arrived Home's Private Credit Fund's has historically paid an annualized dividend yield of 8.1%*, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum. Photo: Shutterstock This article Economists Flip To Trump's Side After Jobs Data–And Jerome Powell Is Now In Trouble originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
